Paper Details

  1. Home
  2. Paper Details

Idelalisib may have the potential to increase radiotherapy side effects.

Author: DistelLuitpold V, FietkauRainer, GoerigNicole, GrycThomas, PutzFlorian, SchusterBarbara, ZieglerSonia

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study focuses on idelalisib, a potent and selective phosphatidylinositol 3-kinase-δ (PI3K-δ) inhibitor, and its application in treating relapsed chronic lymphocytic leukemia, follicular B-cell non-Hodgkin's lymphoma, and small lymphocytic lymphoma. The study highlights idelalisib's selective targeting of PI3K-δ, which is primarily expressed in B-cells, and its potential for effectively inhibiting proliferation in malignant B-cells.
Paper Details　
Original Abstract of the Article :
Idelalisib is approved for the treatment of relapsed chronic lymphocytic leukemia together with Rituximab and for monotherapy of follicular B-cell non-Hodgkin's lymphoma and small lymphocytic lymphoma. It is a potent and selective phosphatidylinositol 3-kinase-δ (PI3K-δ) inhibitor. PI3K-δ primarily ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490234/

データ提供：米国国立医学図書館（NLM）

Idelalisib: A Potential for Increased Radiotherapy Side Effects

Idelalisib, a potent inhibitor of PI3K-δ, is used to treat certain types of B-cell lymphomas. This study explores the potential for idelalisib to increase the side effects of radiotherapy. The researchers highlight the need to be aware of this potential interaction and to monitor patients receiving both idelalisib and radiotherapy closely.

Idelalisib and Radiotherapy: A Potential for Increased Side Effects

The study suggests that idelalisib might potentiate the side effects of radiotherapy, potentially leading to more severe complications. The researchers caution healthcare professionals to be aware of this potential interaction and to consider the potential risks when prescribing idelalisib to patients undergoing radiotherapy.

Navigating Treatment Options: A Careful Approach

This study emphasizes the importance of careful consideration and monitoring when combining idelalisib with radiotherapy. The researchers highlight the need for a thorough understanding of potential drug interactions and for vigilant patient monitoring to mitigate potential risks and optimize treatment outcomes. It's essential to consult with healthcare professionals for personalized guidance and to ensure the safest and most effective treatment approach.

Dr. Camel's Conclusion

The world of medicine, like a vast desert, is filled with complex interactions and potential side effects. This study serves as a reminder to carefully consider the potential risks and benefits of combining different treatments. The researchers highlight the importance of vigilant monitoring and open communication between patients and healthcare providers to ensure the safest and most effective treatment approach.

Date :
  1. Date Completed 2018-04-26
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

28659152

DOI: Digital Object Identifier

PMC5490234

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.